Almanac 2012: Interventional cardiology. The national society journals present selected research that has driven recent advances in clinical cardiology

Hellenic Journal of Cardiology

Volumn 54, Issue 4, 2013, Pages 242-254

  Meier, Pascal ^a   Timmis, Adam ^b  

^a UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^b LONDON CHEST HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; BICARBONATE; BRAIN NATRIURETIC PEPTIDE; CILOSTAZOL; CLOPIDOGREL; CREATINE KINASE MB; ENOXAPARIN; ERYTHROPOIETIN; EVEROLIMUS; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; HIRULOG; PLACEBO; PRASUGREL; RAPAMYCIN; RIMONABANT; TICAGRELOR; TIROFIBAN; TROPONIN;

ABLATION THERAPY; ACUTE CORONARY SYNDROME; ACUTE KIDNEY FAILURE; ANGIOCARDIOGRAPHY; AORTA VALVE STENOSIS; BLEEDING; BLOOD VESSEL OCCLUSION; CAROTID ARTERY OBSTRUCTION; CORONARY ARTERY BYPASS SURGERY; COST EFFECTIVENESS ANALYSIS; DRUG ELUTING STENT; DRUG MEGADOSE; HEART INFARCTION SIZE; HEART VENTRICLE HYPERTROPHY; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; IMPLANTABLE CLIP; INTERVENTIONAL CARDIOVASCULAR PROCEDURE; INTRAVASCULAR ULTRASOUND; META ANALYSIS (TOPIC); MITRAL VALVE REGURGITATION; MITRAL VALVE REPAIR; MORTALITY; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; OPTICAL COHERENCE TOMOGRAPHY; PERCUTANEOUS CORONARY INTERVENTION; PHASE 2 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; STABLE ANGINA PECTORIS; STENT THROMBOSIS; TRANSCATHETER AORTIC VALVE IMPLANTATION;

BIOMEDICAL RESEARCH; CARDIOLOGY; CARDIOVASCULAR DISEASES; DISEASE MANAGEMENT; HUMANS; PERIODICALS AS TOPIC; SOCIETIES, MEDICAL;

EID: 84881040000     PISSN: 11099666     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (115)

1. Gray HH, Henderson RA, de Belder MA, Underwood SR, Camm AJ. Early management of unstable angina and non-ST-segment elevation myocardial infarction: summary of NICE guidance. Heart. 2010; 96: 1662-1668.
2. Boden WE, O'Rourke RA, Teo KK, et al. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med. 2007; 356: 1503-1516.
3. Weintraub WS, Spertus JA, Kolm P, et al. Effect of PCI on quality of life in patients with stable coronary disease. N Engl J Med. 2008; 359: 677-687.
4. Stergiopoulos K, Brown DL. Initial coronary stent implantation with medical therapy vs medical therapy alone for stable coronary artery disease: meta-analysis of randomized con-trolled trials. Arch Intern Med. 2012; 172: 312-319.
5. Henderson RA, O'Flynn N. Management of stable angina: summary of NICE guidance. Heart. 2012; 98: 500-507.
6. Borden WB, Redberg RF, Mushlin AI, Dai D, Kaltenbach LA, Spertus JA. Patterns and intensity of medical therapy in patients undergoing percutaneous coronary intervention. JAMA. 2011; 305: 1882-1889.
7. Aversano T, Lemmon CC, Liu L. Outcomes of PCI at hospitals with or without on-site cardiac surgery. N Engl J Med. 2012; 366: 1792-1802.
8. Singh M, Holmes DR Jr, Dehmer GJ, et al. Percutaneous coronary intervention at centers with and without on-site surgery: a meta-analysis. JAMA. 2011; 306: 2487-2494.
9. Epstein AJ, Polsky D, Yang F, et al. Coronary revascularization trends in the United States, 2001-2008. JAMA. 2011; 305: 1769-76.
10. Taggart DP, Boyle R, de Belder MA, et al. The 2010 ESC/ EACTS guidelines on myocardial revascularisation. Heart. 2011; 97: 445-446.
11. Chan PS, Patel MR, Klein LW, et al. Appropriateness of percutaneous coronary intervention. JAMA. 2011; 306: 53-61.
12. Cohen DJ, Van Hout B, Serruys PW, et al. Quality of life after PCI with drug-eluting stents or coronary-artery bypass surgery. N Engl J Med. 2011; 364: 1016-1026.
13. Weintraub WS, Grau-Sepulveda MV, Weiss JM, et al. Comparative effectiveness of revascularization strategies. N Engl J Med. 2012; 366: 1467-1476.
14. Rao SV, Kaltenbach LA, Weintraub WS, et al. Prevalence and outcomes of same-day discharge after elective percutaneous coronary intervention among older patients. JAMA. 2011; 306: 1461-1467.
15. Khawaja FJ, Shah ND, Lennon RJ, et al. Factors associated with 30-day readmission rates after percutaneous coronary intervention. Arch Intern Med. 2012; 172: 112-117.
16. Brennan JM, Dai D, Patel MR, et al. Characteristics and long-term outcomes of percutaneous revascularization of unprotected left main coronary artery stenosis in the United States: a report from the National Cardiovascular Data Registry, 2004 to 2008. J Am Coll Cardiol. 2012; 59: 648-654.
17. Park SJ, Kim YH, Park DW, et al. Randomized trial of stents versus bypass surgery for left main coronary artery disease. N Engl J Med. 2011; 364: 1718-1727.
18. Torre de la Hernandez JM, Hernández Hernandez F, Alfonso F, et al. Prospective application of pre-defined intravascular ultrasound criteria for assessment of intermediate left main coronary artery lesions results from the multicenter LI-TRO study. J Am Coll Cardiol. 2011; 58: 351-358.
19. Garg S, Serruys PW. Drug-eluting stents: a reappraisal. Heart. 2010; 96: 489-493.
20. de Waha A, Dibra A, Kufner S, et al. Long-term outcome after sirolimus-eluting stents versus bare metal stents in patients with diabetes mellitus: a patient-level meta-analysis of randomized trials. Clin Res Cardiol. 2011; 100: 561-570.
21. Baber U, Mehran R, Sharma SK, et al. Impact of the everolimus-eluting stent on stent thrombosis: a meta-analysis of 13 randomized trials. J Am Coll Cardiol. 2011; 58: 1569-1577.
22. Palmerini T, Biondi-Zoccai G, Della Riva D, et al. Stent thrombosis with drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis. Lancet. 2012; 379: 1393-1402.
23. Meier P, Brilakis ES, Corti R, Knapp G, Shishehbor MH, Gurm HS. Drug-eluting versus bare-metal stent for treatment of saphenous vein grafts: a meta-analysis. PLoS One. 2010; 5: e11040.
24. Kalesan B, Pilgrim T, Heinimann K, et al. Comparison of drug-eluting stents with bare metal stents in patients with ST-segment elevation myocardial infarction. Eur Heart J. 2012; 33: 977-987.
25. Serruys PW, Onuma Y, Dudek D, et al. Evaluation of the second generation of a bioresorbable everolimus-eluting vascular scaffold for the treatment of de novo coronary artery stenosis: 12-month clinical and imaging outcomes. J Am Coll Cardiol. 2011; 58: 1578-1588.
26. Johnman C, Pell JP, Mackay DF, et al. Clinical outcomes following radial versus femoral artery access in primary or rescue percutaneous coronary intervention in Scotland: retrospective cohort study of 4534 patients. Heart. 2012; 98: 552-557.
27. Patterson T, Foale RA. If the radial artery is the new standard of care in primary percutaneous coronary intervention, why is most intervention done by the femoral approach? Heart. 2011; 97: 521-522.
28. Cayla G, Silvain J, Barthelemy O, et al. Trans-radial approach for catheterisation in non-ST segment elevation acute coronary syndrome: an analysis of major bleeding complications in the ABOARD Study. Heart. 2011; 97: 887-891.
29. Mamas MA, Ratib K, Routledge H, et al. Influence of access site selection on PCI-related adverse events in patients with STEMI: meta-analysis of randomised controlled trials. Heart. 2012; 98: 303-311.
30. Vink MA, Amoroso G, Dirksen MT, et al. Routine use of the transradial approach in primary percutaneous coronary intervention: procedural aspects and outcomes in 2209 patients treated in a single high-volume centre. Heart. 2011; 97: 1938-1942.
31. Amoroso G, Kiemeneij F. Transradial access for primary percutaneous coronary intervention: the next standard of care? Heart. 2010; 96: 1341-1344.
32. Vuurmans T, Byrne J, Fretz E, et al. Chronic kidney injury in patients after cardiac catheterisation or percutaneous coronary intervention: a comparison of radial and femoral approaches (from the British Columbia Cardiac and Renal Registries). Heart. 2010; 96: 1538-1542.
33. Jolly SS, Yusuf S, Cairns J, et al. Radial versus femoral access for coronary angiography and intervention in patients with acute coronary syndromes (RIVAL): a randomised, parallel group, multicentre trial. Lancet. 2011; 377: 1409-1420.
34. Siller-Matula JM, Huber K, Christ G, et al. Impact of clopidogrel loading dose on clinical outcome in patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis. Heart. 2011; 97: 98-105.
35. Patti G, Barczi G, Orlic D, et al. Outcome comparison of 600-and 300-mg loading doses of clopidogrel in patients undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: results from the ARMYDA-6 Ml (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Myocardial Infarction) randomized study. J Am Coll Cardiol. 2011; 58: 1592-1599.
36. Breet NJ, van Werkum JW, Bouman HJ, et al. High on-treatment platelet reactivity to both aspirin and clopidogrel is associated with the highest risk of adverse events following percutaneous coronary intervention. Heart. 2011; 97: 983-990.
37. Bouman HJ, Harmsze AM, van Werkum JW, et al. Variability in on-treatment platelet reactivity explained by CY-P2C19*2 genotype is modest in clopidogrel pretreated patients undergoing coronary stenting. Heart. 2011; 97: 1239-1244.
38. Park KW, Park JJ, Lee SP, et al. Cilostazol attenuates ontreatment platelet reactivity in patients with CYP2C19 loss of function alleles receiving dual antiplatelet therapy: a genetic substudy of the CILON-T randomised controlled trial. Heart. 2011; 97: 641-647.
39. Price MJ, Berger PB, Teirstein PS, et al. Standardvs highdose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA. 2011; 305: 1097-1105.
40. Sambu N. Dent H, Englyst N, et al. Effect of clopidogrel withdrawal on platelet reactivity and vascular inflammatory biomarkers 1 year after drug-eluting stent implantation: results of the prospective, single-centre CESSATION study. Heart. 2011; 97: 1661-1667.
41. Warner TD, Armstrong PC, Curzen NP, Mitchell JA. Dual antiplatelet therapy in cardiovascular disease: does aspirin increase clinical risk in the presence of potent P2Y12 receptor antagonists? Heart. 2010; 96: 1693-1694.
42. Smit JJ, van Werkum JW, ten Berg J, et al. Prehospital triple antiplatelet therapy in patients with acute ST elevation myocardial infarction leads to better platelet aggregation inhibition and clinical outcome than dual antiplatelet therapy. Heart. 2010; 96: 1815-1820.
43. Hill RA, Chung H, George E, Longson C, Stevens A. Prasugrel for the treatment of acute coronary syndromes with percutaneous coronary intervention: NICE technology appraisal guidance. Heart. 2010; 96: 1407-1408.
44. Eshaghian S, Shah PK, Kaul S. Advances in antiplatelet treatment for acute coronary syndromes. Heart. 2010; 96: 656-661.
45. Wiviott SD, Braunwald E, McCabe CH, et al. TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007; 357: 2001-2015.
46. Wallentin L, Becker RC, Budaj A, et al. PLATO Investigators, Freij A, Thorsen M. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009; 361: 1045-1057.
47. Mahoney EM, Wang K, Arnold SV, et al. Cost-effectiveness of prasugrel versus clopidogrel in patients with acute coronary syndromes and planned percutaneous coronary intervention: results from the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with Prasugrel-Thrombolysis in myocardial infarction TRITON-TIMI 38. Circulation. 2010; 121: 71-79.
48. Nikolic E, Janzon M, Hauch O, et al. Cost-effectiveness of treating acute coronary syndrome patients with ticagrelor for 12 months: results from the PLATO study. Eur Heart J. Published Online First: 19 June 2012.
49. Hochtl T, Farhan S, Wojta J, et al. New anticoagulant agents in acute coronary syndromes. Heart. 2010; 97: 244-252.
50. Stone GW, Witzenbichler B, Guagliumi G, et al; HORI-ZONS-AMI Trial Investigators. Heparin plus a glycoprotein llb/llla inhibitor versus bivalirudin monotherapy and paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction (HORIZONS-AMI): final 3-year results from a multicentre, randomised controlled trial. Lancet. 2011; 377: 2193-204.
51. Schwenkglenks M, Toward TJ, Plent S, Szucs TD, Blackman DJ, Baumbach A. Cost-effectiveness of bivalirudin versus heparin plus glycoprotein IIb/IIIa inhibitor in the treatment of acute ST-segment elevation myocardial infarction. Heart. 2012; 98: 544-551.
52. Koutouzis M, Lagerqvist B, James S, et al. Unfractionated heparin administration in patients treated with bivalirudin during primary percutaneous coronary intervention is associated lower mortality and target lesion thrombosis: a report from the Swedish Coronary Angiography and Angioplasty Registry (SCAAR). Heart. 2011; 97: 1484-1488.
53. Langrish JP, Fox KA. Optimal antithrombotic treatment during primary percutaneous coronary intervention? Heart. 2011; 97: 1459-1460.
54. Silvain J, Beygui F, Barthélémy O, et al. Efficacy and safety of enoxaparin versus unfractionated heparin during percutaneous coronary intervention: systematic review and meta-analysis. BMJ. 2012; 344: e553.
55. Parise H, Maehara A, Stone GW, Leon MB, Mintz GS. Meta-analysis of randomized studies comparing intravascular ultrasound versus angiographic guidance of percutaneous coronary intervention in pre-drug-eluting stent era. Am J Cardiol. 2011; 107: 374-382.
56. Gauss S, Achenbach S, Pflederer T, Schuhbäck A, Daniel WG, Marwan M. Assessment of coronary artery remodelling by dual-source CT: a head-to-head comparison with intravascular ultrasound. Heart. 2011; 97: 991-997.
57. Schepis T, Marwan M, Pflederer T, et al. Quantification of non-calcified coronary atherosclerotic plaques with dualsource computed tomography: comparison with intravascular ultrasound. Heart. 2010; 96: 610-615.
58. Tahara S, Bezerra HG, Sirbu V, et al. Angiographic, IVUS and OCT evaluation of the long-term impact of coronary disease severity at the site of overlapping drug-eluting and bare metal stents: a substudy of the ODESSA trial. Heart. 2010; 96: 1574-1578.
59. Inoue T, Shite J, Yoon J, et al. Optical coherence evaluation of everolimus-eluting stents 8 months after implantation. Heart. 2010; 97: 1379-1384.
60. Stone GW, Maehara A, Lansky AJ, et al. A prospective natural-history study of coronary atherosclerosis. N Engl J Med. 2011; 364: 226-235.
61. Li QX, Fu QQ, Shi SW, et al. Relationship between plasma inflammatory markers and plaque fibrous cap thickness determined by intravascular optical coherence tomography. Heart. 2010; 96: 196-201.
62. Her SH, Yoo KD, Park CS, et al. Long-term clinical outcomes of overlapping heterogeneous drug-eluting stents compared with homogeneous drug-eluting stents. Heart. 2011; 97: 1501-1506.
63. Behan MW, Holm NR, Curzen NP, et al. Simple or complex stenting for bifurcation coronary lesions: a patient-level pooledanalysis of the Nordic Bifurcation Study and the British Bifurcation Coronary Study. Circ Cardiovasc Interv. 2011; 4: 57-64.
64. Gwon HC, Hahn JY, Koo BK, et al. Final kissing ballooning and long-term clinical outcomes in coronary bifurcation lesions treated with 1-stent technique: results from the COBIS registry. Heart. 2011; 98: 225-231.
65. Mills NL, Churchhouse AM, Lee KK, et al. Implementation of a sensitive troponin I assay and risk of recurrent myocardial infarction and death in patients with suspected acute coronary syndrome. JAMA. 2011; 305: 1210-1216.
66. Jaffe AS, Apple FS, Morrow DA, Lindahl B, Katus HA. Being rational about (im)precision: a statement from the Biochemistry Subcommittee of the Joint European Society of Cardiology/American College of Cardiology Foundation/ American Heart Association/World Heart Federation Task Force for the definition of myocardial infarction. Clin Chem. 2010; 56: 941-943.
67. Mills NL, Lee KK, McAllister DA, et al. Implications of lowering threshold of plasma troponin concentration in diagnosis of myocardial infarction: cohort study. BMJ. 2012; 344: e1533.
68. Baker JO, Reinhold J, Redwood S, Marber MS. Troponins: redefining their limits. Heart. 2011; 97: 447-452.
69. Korosoglou G, Lehrke S, Mueller D, et al. Determinants of troponin release in patients with stable coronary artery disease: insights from CT angiography characteristics of atherosclerotic plaque. Heart. 2011; 97: 823-831.
70. Goodacre SW, Bradburn M, Cross E, Collinson P, Gray A, Hall AS. The Randomised Assessment of Treatment using Panel Assay of Cardiac Markers (RATPAC) trial: a randomised controlled trial of point-of-care cardiac markers in the emergency department. Heart. 2011; 97: 190-196.
71. Fox KA, Eagle KA, Gore JM, et al. The Global registry of acute coronary events, 1999 to 2009-GRACE. Heart. 2010; 96: 1095-101.
72. Jolly SS, Shenkman H, Brieger D, et al. Quantitative troponin and death, cardiogenic shock, cardiac arrest and new heart failure in patients with non-ST-segment elevation acute coronary syndromes (NSTE ACS): insights from the Global Registry of Acute Coronary Events. Heart. 2011; 97: 197-202.
73. Politi L, Sgura F, Rossi R, et al. A randomised trial of targetvessel versus multi-vessel revascularisation in ST-elevation myocardial infarction: major adverse cardiac events during long-term follow-up. Heart. 2010; 96: 662-667.
74. Vlaar PJ, Mahmoud KD, Holmes DR Jr, et al. Culprit vessel only versus multivessel and staged percutaneous coronary intervention for multivessel disease in patients presenting with ST-segment elevation myocardial infarction: a pairwise and network meta-analysis. J Am Coll Cardiol. 2011; 58: 692-703.
75. Kornowski R, Mehran R, Dangas G, et al. Prognostic impact of staged versus "one-time" multivessel percutaneous intervention in acute myocardial infarction: analysis from the HORIZONS-AMI (harmonizing outcomes with revascularization and stents in acute myocardial infarction) trial. J Am Coll Cardiol. 2011; 58: 704-711.
76. Suárez-Barrientos A, López-Romero P, Vivas D, et al. Circadian variations of infarct size in acute myocardial infarction. Heart. 2011; 97: 970-976.
77. Eitel I, Desch S, de Waha S, et al. Long-term prognostic value of myocardial salvage assessed by cardiovascular magnetic resonance in acute reperfused myocardial infarction. Heart. 2011; 97: 2038-2045.
78. Mather AN, Fairbairn TA, Ball SG, Greenwood JP, Plein S. Reperfusion haemorrhage as determined by cardiovascular MRI is a predictor of adverse left ventricular remodelling and markers of late arrhythmic risk. Heart. 2011; 97: 453-459.
79. O'Regan DP, Ariff B, Neuwirth C, Tan Y, Durighel G, Cook SA. Assessment of severe reperfusion injury with T2* cardiac MRI in patients with acute myocardial infarction. Heart. 2010; 96: 1885-1891.
80. Kharbanda RK. Cardiac conditioning: a review of evolving strategies to reduce ischaemia-reperfusion injury. Heart. 2010; 96: 1179-1186.
81. Ludman AJ, Yellon DM, Hasleton J, et al. Effect of erythropoietin as an adjunct to primary percutaneous coronary intervention: a randomised controlled clinical trial. Heart. 2011; 97: 1560-1565.
82. Pedersen CM, Schmidt MR, Barnes G, et al. Bradykinin does not mediate remote ischaemic preconditioning or ischaemiareperfusion injury in vivo in man. Heart. 2011; 97: 1857-1861.
83. Ikonomidis I, Iliodromitis EK, Tzortzis S, et al. Staccato reperfusion improves myocardial microcirculatory function and long-term left ventricular remodelling: a randomised contrast echocardiography study. Heart. 2010; 96: 1898-1903.
84. Sörensson P, Saleh N, Bouvier F, et al. Effect of postconditioning on infarct size in patients with ST elevation myocardial infarction. Heart. 2010; 96: 1710-1715.
85. Patel MR, Smalling RW, Thiele H, et al. Intra-aortic balloon counterpulsation and infarct size in patients with acute anterior myocardial infarction without shock: the CRISP AMI randomized trial. JAMA. 2011; 306: 1329-1337.
86. Reed M, Meier P, Tamhane UU, Welch KB, Moscucci M, Gurm HS. The relative renal safety of iodixanol compared with low-osmolar contrast media: a meta-analysis of randomized controlled trials. JACC Cardiovasc Interv. 2009; 2: 645-654.
87. Wi J, Ko YG, Kim JS, et al. Impact of contrast-induced acute kidney injury with transient or persistent renal dysfunction on long-term outcomes of patients with acute myocardial infarction undergoing percutaneous coronary intervention. Heart. 2011; 97: 1753-1757.
88. Gallagher S, Knight C. Contrast-induced nephropathy in primary percutaneous coronary intervention. Heart. 2011; 97: 1723-1725.
89. Meier PP, Gurm HS. Is simpler also better? Brief sodium bicarbonate infusion to prevent contrast-induced nephropathy. Am J Cardiol. 2010; 105: 1042-1043.
90. Hekimian G, Kim M, Passefort S, et al. Preoperative use and safety of coronary angiography for acute aortic valve infective endocarditis. Heart. 2010; 96: 696-700.
91. O'Leary DH, Reuwer AQ, Nissen SE, et al. Effect of rimonabant on carotid intima-media thickness (CIMT) progression in patients with abdominal obesity and metabolic syndrome: the AUDITOR Trial. Heart. 2011; 97: 1143-1150.
92. Roffi M. Peripheral arterial disease. Current evidence for carotid endarterectomy and carotid artery stenting. Heart. 2010; 96: 636-642.
93. Brott TG, Hobson RW 2nd, Howard G, et al; CREST Investigators. Stenting versus endarterectomy for treatment of carotid-artery stenosis. N Engl J Med. 2010; 363: 11-23.
94. Meier P, Knapp G, Tamhane U, Chaturvedi S, Gurm HS. Short term and intermediate term comparison of endarterectomy versus stenting for carotid artery stenosis: systematic review and meta-analysis of randomised controlled clinical trials. BMJ. 2010; 340: c467.
95. Neequaye SK, Halliday AW. Carotid artery stenting: the 2011 NICE guidelines. Heart. 2011; 98: 274-5.
96. Venkatachalam S, Gray BH, Mukherjee D, Shishehbor MH. Contemporary management of concomitant carotid and coronary artery disease. Heart. 2011; 97: 175-180.
97. Xie W, Liang L, Zhao L, et al. Combination of carotid intima-media thickness and plaque for better predicting risk of ischaemic cardiovascular events. Heart. 2011; 97: 1326-1331.
98. Kodali SK, Williams MR, Smith CR, et al. Two-year out-comes after transcatheter or surgical aortic-valve replacement. N Engl J Med. 2012; 366: 1686-1695.
99. Abdel-Wahab M, Zahn R, Horack M, et al. Aortic regurgitation after transcatheter aortic valve implantation: incidence and early outcome. Results from the German transcatheter aortic valve interventions registry. Heart. 2010; 97: 899-906.
100. Rodés-Cabau J, Gutiérrez M, Bagur R, et al. Incidence, predictive factors, and prognostic value of myocardial injury following uncomplicated transcatheter aortic valve implantation. J Am Coll Cardiol. 2011; 57: 1988-1999.
101. Reynolds MR, Magnuson EA, Lei Y, et al. Health-related quality of life after transcatheter aortic valve replacement in inoperable patients with severe aortic stenosis. Circulation. 2011; 124: 1964-1972.
102. Gotzmann M, Hehen T, Germing A, et al. Short-term effects of transcatheter aortic valve implantation on neurohormonal activation, quality of life and 6-minute walk test in severe and Sym ptomatic aortic stenosis. Heart. 2010; 96: 1102-1106.
103. Watt M, Mealing S, Eaton J, et al. Cost-effectiveness of transcatheter aortic valve replacement in patients ineligible for conventional aortic valve replacement. Heart. 2012; 98: 370-376.
104. Reynolds MR, Magnuson EA, Wang K, et al. Cost-effectiveness of transcatheter aortic valve replacement compared with standard care among inoperable patients with severe aortic stenosis: results from the placement of aortic transcatheter valves (PARTNER) trial (Cohort B). Circulation. 2012; 125: 1102-1109.
105. Piazza N, Otten A, Schultz C, et al. Adherence to patient selection criteria in patients undergoing transcatheter aortic valve implantation with the 18F CoreValve ReValving System. Heart. 2010; 96: 19-26.
106. Tamburino C, Capodanno D, Ussia GP. TAVI as a threat to surgical practice: "much ado about nothing" or "the quiet before the storm"? Heart. 2010; 96: 1609-1610.
107. Grant SW, Devbhandari MP, Grayson AD, et al. What is the impact of providing a transcatheter aortic valve implantation service on conventional aortic valve surgical activity: patient risk factors and outcomes in the first 2 years. Heart. 2010; 96: 1633-1637.
108. Farouque HM, Clark DJ. Percutaneous mitral valve leaflet repair for mitral regurgitation: NICE guidance. Heart. 2010; 96: 385-387.
109. Feldman T, Kar S, Rinaldi M, et al. Percutaneous mitral repair with the MitraClip system: safety and midterm durability in the initial EVEREST (Endovascular Valve Edge-to-Edge REpair Study) cohort. J Am Coll Cardiol. 2009; 54: 686-694.
110. Glower D, Ailawadi G, Argenziano M, et al. EVEREST II randomized clinical trial: predictors of mitral valve replacement in de novo surgery or after the MitraClip procedure. J Thorac Cardiovasc Surg. 2012; 143: S60-63.
111. Gaemperli O, Moccetti M, Surder D, et al. Acute haemodynamic changes after percutaneous mitral valve repair: relation to mid-term outcomes. Heart. 2012; 98: 126-132.
112. Nagueh SF, Groves BM, Schwartz L, et al. Alcohol septal ablation for the treatment of hypertrophic obstructive cardiomyopathy. A multicenter North American registry. J Am Coll Cardiol. 2011; 58: 2322-2328.
113. Ball W, Ivanov J, Rakowski H, et al. Long-term survival in patients with resting obstructive hypertrophic cardiomyopathy comparison of conservative versus invasive treatment. J Am Coll Cardiol. 2011; 58: 2313-2321.
114. Galve E, Sambola A, Saldana G, et al. Late benefits of dualchamber pacing in obstructive hypertrophic cardiomyopathy: a 10-year follow-up study. Heart. 2010; 96: 352-356.
115. Jensen MK, Almaas VM, Jacobsson L, et al. Long-term outcome of percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: a Scandinavian multicenter study. Circ Cardiovasc Interv. 2011; 4: 256-265.